Who Paid My Doc
Jennifer Cera
Nurse Practitioner, Obstetrics & Gynecology Omaha, NE Nurse Practitioner
NPI 1508970732 CMS profile 11194656
988102 Nebraska Medical Ctr, Omaha, NE 68198
General payments
$5,216
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jennifer Cera of Omaha, NE is reported in the CMS Open Payments database as having received $5,216 across 15 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 97th percentile of Nurse Practitioner, Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
4 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,132 | 8 | |
| 2024 | General | $1,982 | 5 | |
| 2023 | General | $15 | 1 | |
| 2022 | General | $86 | 1 |
Beside peers
- Jennifer Cera
- Nurse Practitioner, Obstetrics & Gynecology median
- Middle half of Nurse Practitioner, Obstetrics & Gynecology
- National median
In program year 2025, general payments to Jennifer Cera were reported at $3,132. Among 1,030 Nurse Practitioner, Obstetrics & Gynecology profiles paid that year, the median was $151 and the middle half received between $51 and $371.
Show as a table
| Year | Jennifer Cera | Nurse Practitioner, Obstetrics & Gynecology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $0 | $135 | $40–$338 | $132 |
| 2022 | $86 | $143 | $45–$386 | $149 |
| 2023 | $15 | $153 | $54–$411 | $160 |
| 2024 | $1,982 | $140 | $45–$326 | $164 |
| 2025 | $3,132 | $151 | $51–$371 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 7 drugsPart D claims
265
Drug cost
$58,251
Branded share of claims
51.7%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Myrbetriq Mirabegron | Brand | 45 | $34,708 | |
| Gemtesa Vibegron | Brand | 22 | $15,332 | |
| Estradiol | Generic | 57 | $4,117 | |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | Brand | 32 | $1,314 | |
| Solifenacin Succinate | Generic | 51 | $1,264 | |
| Trospium Chloride | Generic | 20 | $768 | |
| Oxybutynin Chloride Er Oxybutynin Chloride | Brand | 38 | $747 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 11 billing codesPaid by Medicare
$8,765
Medicare patients
68
Services billed
209
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 66% | |
| Arthritis | 57% | |
| Depression | 32% | |
| Osteoporosis | 32% | |
| Diabetes | 26% | |
| Chronic kidney disease | 21% | |
| Heart failure | 19% | |
| Ischemic heart disease | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
15 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Obstetrics & Gynecology in Nebraska
Mindy Rathe
Nurse Practitioner, Obstetrics & Gynecology · Omaha, NE
Jessica Gering
Nurse Practitioner, Obstetrics & Gynecology · Papillion, NE
Julie Welsh
Nurse Practitioner, Obstetrics & Gynecology · Scottsbluff, NE
Andrea Carkoski
Nurse Practitioner, Obstetrics & Gynecology · Grand Island, NE
Mary Tompkins
Nurse Practitioner, Obstetrics & Gynecology · Scottsbluff, NE
Lindsay Van Pelt
Nurse Practitioner, Obstetrics & Gynecology · Grand Island, NE
Related records
Nurse Practitioner, Obstetrics & Gynecology in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Obstetrics & Gynecology
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.